Business
Appointment Dr.Christina Coughlin as a consultant
Appointment Dr.Christina Coughlin as a consultant.
About this update from Avacta Group Plc
[{"type":"text","content":"\n\n \n \n \n \n \n\n20 September 2023\nAvacta Group plc\n \n(\"Avacta\" or the \"Group\" or the \"Company\")\n \nAppointment of Dr. Christina Coughlin as a consultant\n \nRelated party transaction notification\n \nAvacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, today announces that, according to the AIM rules governing Related Party Transactions, that it has entered into a consultancy agreement with Dr. Christina Coughlin (the \"Consultancy Agreement\"), currently a Non-Executive Director of the Group, as it seeks to appoint a full-time Chief Medical Officer.\n \nThe continuing very positive clinical progress of AVA6000 has validated the tumour targeting capability of the pre|CISIONTM platform. This has opened up the potential for multiple commercial opportunities, and the scope for using pre|CISIONTM to create a pipeline of new tumour-targeted cancer therapies is extensive. The Company's clinical strategy is key to fully exploiting this opportunity through a combination of in-house development and an active licensing and commercial partnerships programme. Therefore, the Company is seeking to add a full-time Chief Medical Officer (CMO) with responsibility for driving the Company's clinical strategy.\n \nIn advance of appointing a full-time CMO, the Company will leverage the expertise of Dr. Coughlin on a temporary basis through the Consultancy Agreement. Dr. Coughlin is a highly experienced clinical oncologist with a broad background in biotechnology, global pharmaceuticals, and comprehensive experience in drug development from pre-IND to filing. Dr Coughlin also has a proven track record of building drug development teams in global companies.\n \n \nDr. Coughlin, M.D., Ph.D. was previously the Chief Executive Officer of Cytolmmune Therapeutics LLC, a clinical-stage biotechnology company, focused on the development and commercialisation of novel cancer immunotherapy products designed to use the patient's own immune system to eliminate cancer cells. She also served as Chief Medical Officer to Rubius Therapeutics. Inc, where she led the clinical development, translational medicine and regulatory efforts in the allogeneic red cell therapy platform. Prior to Rubius, Dr. Coughlin was with Tm...